Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCOPE-BD: Scopolamine for Bipolar Depression
2017-003112-39Phase 2Completed
- Sponsor
- University of Galway
- Start
- Sep 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bipolar disorder (BD) comparing Scopolamine with Placebo (2 arms). Primary endpoint: Primary: Change in HDRS score. Started Sep 2019; status: completed.
02
Drugs
scopolamine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on 2017-003112-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003112-39.